Neurocrine Biosciences, Inc. (NBIX) |
|
104.94 -1.17 (-1.1%)
|
08-18 06:34 |
|
Open: |
106.03 |
Pre. Close: |
106.11 |
|
High:
|
106.47 |
Low:
|
104.56 |
|
Volume:
|
499,932 |
Market Cap:
|
10,036(M) |
|
|
|
|
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
106.52 - 107.23 |
107.23 - 107.83 |
|
Low:
|
103.18 - 103.88 |
103.88 - 104.46 |
|
Close:
|
103.91 - 105.05 |
105.05 - 105.99 |
|
Technical analysis |
as of: 2022-08-17 4:25:20 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 127.61 One year: 149.05 |
| Support: |
Support1: 98.3 Support2: 91.52 |
| Resistance: |
Resistance1: 109.26 Resistance2: 127.61 |
| Pivot: |
100.98  |
| Moving Average: |
MA(5): 105.79  MA(20): 99.65
MA(100): 94.31 MA(250): 91.42 |
| MACD: |
MACD(12,26): 3 Signal(9): 2.3 |
| Stochastic oscillator: |
%K(14,3): 82.4 %D(3): 82.5 |
| RSI: |
RSI(14): 61.6 |
| 52-week: |
High: 109.26 Low: 71.87 |
| Average Vol(K): |
3-Month: 762 (K) 10-Days: 1,058 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NBIX ] has closed below upper band by 33.5%. Bollinger Bands are 105.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue. |
|
|
Headline News |
Thu, 18 Aug 2022
Toronto Dominion Bank Cuts Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World
Wed, 10 Aug 2022
Mizuho Increases Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $98.00 - Defense World
Wed, 10 Aug 2022
Neurocrine Biosciences (NASDAQ:NBIX) Sets New 12-Month High on Analyst Upgrade - Defense World
Tue, 09 Aug 2022
Neurocrine Biosciences (NASDAQ:NBIX) Upgraded to “Strong-Buy” at StockNews.com - Defense World
Sun, 07 Aug 2022
Neurocrine Biosciences (NASDAQ:NBIX) PT Raised to $125.00 at Robert W. Baird - Defense World
Fri, 05 Aug 2022
Neurocrine Biosciences (NBIX) Q2 2022 Earnings Call Transcript - The Motley Fool
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
95 (M) |
| Shares Float |
94 (M) |
|
% Held by Insiders
|
1.3 (%) |
|
% Held by Institutions
|
99.5 (%) |
|
Shares Short
|
2,600 (K) |
|
Shares Short P.Month
|
3,730 (K) |
Stock Financials |
|
EPS
|
4.53 |
|
EPS Est Next Qtl
|
-0.41 |
|
EPS Est This Year
|
-2.46 |
|
EPS Est Next Year
|
-1.71 |
|
Book Value (p.s.)
|
14.19 |
|
Profit Margin (%)
|
5.9 |
|
Operating Margin (%)
|
14.8 |
|
Return on Assets (ttm)
|
5.6 |
|
Return on Equity (ttm)
|
5.5 |
|
Qtrly Rev. Growth
|
31.2 |
|
Gross Profit (p.s.)
|
8.33 |
|
Sales Per Share
|
12.75 |
|
EBITDA (p.s.)
|
2.01 |
|
Qtrly Earnings Growth
|
-57.6 |
|
Operating Cash Flow
|
129 (M) |
|
Levered Free Cash Flow
|
153 (M) |
Stock Valuations |
|
PE Ratio
|
23.11 |
|
PEG Ratio
|
-17.9 |
|
Price to Book value
|
7.39 |
|
Price to Sales
|
8.22 |
|
Price to Cash Flow
|
77.35 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
1995-12-28 |
|
7 Binary Options
|
|
Your Ad Here
|
|
